Pete - I think K would be very, very needed. Intra-arterial
Pete - I think K would be very, very needed. Intra-arterial administration of chemo drugs has been huge treatment progress for these kids - but the meds being administered this way are still the harsh chemotherapeutic agents we're used to. Because they are being delivered directly to the ocular site - the systemic risks and side effects have been reduced dramatically - but who wants these agents going into their kids bodies? If a much safer, much less toxic alternative came around with equal or better efficacy - what parent wouldn't choose it?
The hereditary form of this disease is so dangerous. Clinicians have their hands tied. These kids are much higher risk, get hit earlier, get hit in both eyes most often, get secondary cancers at high rates...They need to be treated aggressively, often need a mutiple chemo-regimen that can have side effect of...(wait for it!)...CANCER - in the form of leukemia. Also they sometimes (rare but still happens) need radiation even though radiation is known to increase risk for later cancers, a risk already so high for them. So - in this group of kids with error in the RB1 gene, with hereditary retinoblastoma, Kevetrin could be a godsend. It could give them full body coverage without the system poisoning of chemo. It could prevent radiation treatment in those most unfortunate of children whose illnesses still force them to make that choice.
Also - the chance exists that with Kevetrin, those kids with hereditary retinoblastoma may have decreased risk of pineal gland and other cancers. All supposition. So early in testing to be making any such claims. Just a dream for now - we have no idea if this will be possible.
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...
Continue Reading
Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...
Continue Reading
GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...
Continue Reading
Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...
Continue Reading
The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...
Continue Reading
The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...
Continue Reading
Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...
Continue Reading
The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...
Continue Reading
Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...
Continue Reading
Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....
Continue Reading
Top 5 Most Recently Viewed Articles
Analyzing Coca-Cola's Recent Options Activity Investors are showing a bearish trend toward Coca-Cola (KO), which is an important indicator for retail traders monitoring investment trends. The recent unusual options activity suggests that these investors may possess insights not yet shared with the public. Thus, individual traders should be particularly attentive to these...
Continue Reading
Exploring the Growth of the Sustainable Palm Oil Market The sustainable palm oil market is currently on the rise, fueled by a growing demand for trans-fat-free products and innovations in eco-friendly farming practices. This growth is expected to hit around USD 2.75 billion by 2028, reflecting a solid compound annual growth rate (CAGR) of about 5.24% in the coming years....
Continue Reading
Grilling Safety Tips from Ferrellgas This Labor Day As we gear up for one of the biggest grilling holidays of the year, it's essential to keep safety in mind while savoring delicious meals with family and friends. Ferrellgas Partners, L.P. is taking this opportunity to remind customers about the significance of safe grilling practices this Labor Day. This holiday not only...
Continue Reading
Solstice Gold Completes Successful Private Placement Financing Solstice Gold Corp. (“Solstice”, “we”, “our”, or the “Company”) is thrilled to announce the successful closing of its private placement financing. This significant financial milestone comes with gross proceeds of approximately $150,000 from the issuance of 6,600,000 shares. This private...
Continue Reading
Avanos Medical Launches New CORGRIP SR Advancement to reduce dislodgement in feeding tube retention systems Avanos Medical, Inc. (NYSE: AVNS) recently announced an exciting development in its Enteral Feeding portfolio with the launch of the CORGRIP SR Nasogastric/Nasointestinal Tube Retention System. This innovative design aims to provide enhanced support and security for...
Continue Reading